Advertisement

American Journal of Clinical Dermatology

, Volume 20, Issue 2, pp 237–250 | Cite as

Off-Label Use of Topical Minoxidil in Alopecia: A Review

  • Jenna R. Stoehr
  • Jennifer N. Choi
  • Maria Colavincenzo
  • Stefan VanderweilEmail author
Review Article

Abstract

Topical minoxidil is a well-known and often-utilized drug in dermatological practice for the treatment of alopecia. It was approved by the United States Food and Drug Administration for the treatment of androgenetic alopecia in 1988. Since its approval, minoxidil has been used off-label for the treatment of many other types of alopecia, with minimal formal evidence of efficacy. Conditions for which the use of topical minoxidil has been reported include telogen effluvium, alopecia areata (AA), scarring alopecia, eyebrow hypotrichosis, monilethrix, and chemotherapy-induced alopecia (CIA). The evidence for the use of minoxidil in each condition is derived from a variety of studies, including clinical trials, case series, and case reports. A comprehensive review of the literature indicates that while minoxidil is routinely used in the management of many alopecic conditions, there is mixed evidence for its efficacy. For certain conditions, including AA and most scarring alopecias, the evidence seems to be inconclusive. For others, such as eyebrow hypotrichosis, monilethrix, early traction alopecia, and CIA, there is more support for the efficacy of minoxidil. Although the favorable safety profile of minoxidil is established in adults, its use in the treatment of pediatric alopecia may require heightened monitoring and patient education.

Notes

Compliance with Ethical Standards

Conflict of interest

Jenna R. Stoehr, Jennifer N. Choi, Maria Colavincenzo, and Stefan Vanderweil have no conflicts of interest to declare.

Funding

No sources of funding were used for the preparation of this article.

References

  1. 1.
    Gilmore E, Weil J, Chidsey C. Treatment of essential hypertension with a new vasodilator in combination with beta-adrenergic blockade. N Engl J Med. 1970;282(10):521–7.Google Scholar
  2. 2.
    Gottlieb TB, Katz FH, Chidsey CA 3rd. Combined therapy with vasodilator drugs and beta-adrenergic blockade in hypertension. A comparative study of minoxidil and hydralazine. Circulation. 1972;45(3):571–82.Google Scholar
  3. 3.
    Devine BL, Fife R, Trust PM. Minoxidil for severe hypertension after failure of other hypotensive drugs. Br Med J. 1977;2(6088):667–9.Google Scholar
  4. 4.
    Oka M, Makela M. Minoxidil in severe hypertension. Acta Med Scand. 1978;203(1–2):43–7.Google Scholar
  5. 5.
    Lester W. Hair-raising tale: no fame for men who discovered Rogaine. The Daily Gazette. 1996. p. 17.Google Scholar
  6. 6.
    US FDA. Rogaine (for Men). Report No.: NDA: 019501. Silver Spring, MD: US FDAGoogle Scholar
  7. 7.
    Associated Press. Hair-Growth Drug to Be Sold Over the Counter. New York Times. February 13, 1996.Google Scholar
  8. 8.
    Goh C, Zippin JH. Androgenetic alopecia: diagnosis and treatment with a focus on recent genetic implications. J Drugs Dermatol. 2009;8(2):185–92.Google Scholar
  9. 9.
    Koperski JA, Orenberg EK, Wilkinson DI. Topical minoxidil therapy for androgenetic alopecia. A 30-month study. Arch Dermatol. 1987;123(11):1483–7.Google Scholar
  10. 10.
    Rietschel RL, Duncan SH. Safety and efficacy of topical minoxidil in the management of androgenetic alopecia. J Am Acad Dermatol. 1987;16(3 Pt 2):677–85.Google Scholar
  11. 11.
    Wester RC, Maibach HI, Guy RH, Novak E. Minoxidil stimulates cutaneous blood flow in human balding scalps: pharmacodynamics measured by laser Doppler velocimetry and photopulse plethysmography. J Invest Dermatol. 1984;82(5):515–7.Google Scholar
  12. 12.
    Messenger AG, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186–94.Google Scholar
  13. 13.
    Varothai S, Bergfeld WF. Androgenetic alopecia: an evidence-based treatment update. Am J Clin Dermatol. 2014;15(3):217–30.Google Scholar
  14. 14.
    Phillips TG, Slomiany WP, Allison R. Hair loss: common causes and treatment. Am Fam Physician. 2017;96(6):371–8.Google Scholar
  15. 15.
    Malkud S. Telogen effluvium: a review. J Clin Diagn Res. 2015;9(9):WE01–3.Google Scholar
  16. 16.
    Hughes EC, Taneja A. Telogen effluvium. Treasure Island: StatPearls Publishing; 2018.Google Scholar
  17. 17.
    Garcia-Hernandez MJ, Camacho FM. Chronic telogen effluvium: incidence, clinical and biochemical features, and treatment. Arch Dermatol. 1999;135(9):1123–4.Google Scholar
  18. 18.
    Arck PC, Handjiski B, Peters EM, Hagen E, Klapp BF, Paus R. Topical minoxidil counteracts stress-induced hair growth inhibition in mice. Exp Dermatol. 2003;12(5):580–90.Google Scholar
  19. 19.
    Perera E, Sinclair R. Treatment of chronic telogen effluvium with oral minoxidil: a retrospective study. F1000Res. 2017;6:1650.Google Scholar
  20. 20.
    Dmytriw AA, Morzycki W, Green PJ. Prevention of alopecia in medical and interventional chemotherapy patients. J Cutan Med Surg. 2015;19(1):11–6.Google Scholar
  21. 21.
    Hordinsky M, Donati A. Alopecia areata: an evidence-based treatment update. Am J Clin Dermatol. 2014;15(3):231–46.Google Scholar
  22. 22.
    Galbraith GM, Thiers BH. In vitro suppression of human lymphocyte activity by minoxidil. Int J Dermatol. 1985;24(4):249–51.Google Scholar
  23. 23.
    Shi YP. Topical minoxidil in the treatment of alopecia areata and male-pattern alopecia. Arch Dermatol. 1986;122(5):506.Google Scholar
  24. 24.
    Fenton DA, Wilkinson JD. Topical minoxidil in the treatment of alopecia areata. Br Med J (Clin Res Ed). 1983;287(6398):1015–7.Google Scholar
  25. 25.
    Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol. 1992;128(11):1467–73.Google Scholar
  26. 26.
    Chowdhury MM, Rahman MH, Wahab MA. Efficacy of combination therapy for the management regime of Alopecia areata. Mymensingh Med J. 2007;16(2 Suppl):S19–22.Google Scholar
  27. 27.
    White SI, Friedmann PS. Topical minoxidil lacks efficacy in alopecia areata. Arch Dermatol. 1985;121(5):591.Google Scholar
  28. 28.
    Vestey JP, Savin JA. A trial of 1% minoxidil used topically for severe alopecia areata. Acta Derm Venereol. 1986;66(2):179–80.Google Scholar
  29. 29.
    Shapiro J, Tan J, Ho V, Abbott F, Tron V. Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation. J Am Acad Dermatol. 1993;29(5 Pt 1):729–35.Google Scholar
  30. 30.
    Fransway AF, Muller SA. 3 percent topical minoxidil compared with placebo for the treatment of chronic severe alopecia areata. Cutis. 1988;41(6):431–5.Google Scholar
  31. 31.
    Price VH. Topical minoxidil (3%) in extensive alopecia areata, including long-term efficacy. J Am Acad Dermatol. 1987;16(3 Pt 2):737–44.Google Scholar
  32. 32.
    Farhangian ME, McMichael AJ, Huang KE, Feldman SR. Treatment of alopecia areata in the united states: a retrospective cross-sectional study. J Drugs Dermatol. 2015;14(9):1012–4.Google Scholar
  33. 33.
    Caldwell CC, Saikaly SK, Dellavalle RP, Solomon JA. Prevalence of pediatric alopecia areata among 572,617 dermatology patients. J Am Acad Dermatol. 2017;77(5):980–1.Google Scholar
  34. 34.
    Xu L, Liu KX, Senna MM. A practical approach to the diagnosis and management of hair loss in children and adolescents. Front Med (Lausanne). 2017;4:112.Google Scholar
  35. 35.
    Lenane P, Pope E, Krafchik B. Congenital alopecia areata. J Am Acad Dermatol. 2005;52(2 Suppl 1):8–11.Google Scholar
  36. 36.
    Rai AK. Minoxidil-induced hypertrichosis in a child with alopecia areata. Indian Dermatol Online J. 2017;8(2):147–8.Google Scholar
  37. 37.
    Herskovitz I, Freedman J, Tosti A. Minoxidil induced hypertrichosis in a 2 year-old child. 2013;F1000Res(2):226.Google Scholar
  38. 38.
    Guerouaz N, Mohamed AO. Minoxidil induced hypertrichosis in children. Pan Afr Med J. 2014;18:8.Google Scholar
  39. 39.
    Rampon G, Henkin C, de Souza PR, Almeida HL Jr. Infantile generalized hypertrichosis caused by topical minoxidil. An Bras Dermatol. 2016;91(1):87–8.Google Scholar
  40. 40.
    Georgala S, Befon A, Maniatopoulou E, Georgala C. Topical use of minoxidil in children and systemic side effects. Dermatology. 2007;214(1):101–2.Google Scholar
  41. 41.
    Tanus A, Oliveira CC, Villarreal DJ, Sanchez FA, Dias MF. Black women’s hair: the main scalp dermatoses and aesthetic practices in women of African ethnicity. Bras Dermatol. 2015;90(4):450–65.Google Scholar
  42. 42.
    Kossard S. Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a pattern distribution. Arch Dermatol. 1994;130(6):770–4.Google Scholar
  43. 43.
    Vano-Galvan S, Molina-Ruiz AM, Serrano-Falcon C, Arias-Santiago S, Rodrigues-Barata AR, Garnacho-Saucedo G, et al. Frontal fibrosing alopecia: a multicenter review of 355 patients. J Am Acad Dermatol. 2014;70(4):670–8.Google Scholar
  44. 44.
    Moreno-Ramirez D, Camacho Martinez F. Frontal fibrosing alopecia: a survey in 16 patients. J Eur Acad Dermatol Venereol. 2005;19(6):700–5.Google Scholar
  45. 45.
    Racz E, Gho C, Moorman PW, Noordhoek Hegt V, Neumann HA. Treatment of frontal fibrosing alopecia and lichen planopilaris: a systematic review. J Eur Acad Dermatol Venereol. 2013;27(12):1461–70.Google Scholar
  46. 46.
    Tosti A, Piraccini BM, Iorizzo M, Misciali C. Frontal fibrosing alopecia in postmenopausal women. J Am Acad Dermatol. 2005;52(1):55–60.Google Scholar
  47. 47.
    Esteban-Lucia L, Molina-Ruiz AM, Requena L. Update on frontal fibrosing alopecia. Actas Dermosifiliogr. 2017;108(4):293–304.Google Scholar
  48. 48.
    Davis EC, Reid SD, Callender VD, Sperling LC. Differentiating central centrifugal cicatricial alopecia and androgenetic alopecia in african american men: report of three cases. J Clin Aesthet Dermatol. 2012;5(6):37–40.Google Scholar
  49. 49.
    Herskovitz I, Miteva M. Central centrifugal cicatricial alopecia: challenges and solutions. Clin Cosmet Investig Dermatol. 2016;9:175–81.Google Scholar
  50. 50.
    Miteva M, Tosti A. Pathologic diagnosis of central centrifugal cicatricial alopecia on horizontal sections. Am J Dermatopathol. 2014;36(11):859–64 (quiz 65–7).Google Scholar
  51. 51.
    McMichael AJ. Ethnic hair update: past and present. J Am Acad Dermatol. 2003;48(6 Suppl):S127–33.Google Scholar
  52. 52.
    Gathers RC, Lim HW. Central centrifugal cicatricial alopecia: past, present, and future. J Am Acad Dermatol. 2009;60(4):660–8.Google Scholar
  53. 53.
    Eginli A, Dothard E, Bagayoko CW, Huang K, Daniel A, McMichael AJ. A retrospective review of treatment results for patients with central centrifugal cicatrical alopecia. J Drugs Dermatol. 2017;16(4):317–20.Google Scholar
  54. 54.
    Haskin A, Aguh C. All hairstyles are not created equal: what the dermatologist needs to know about black hairstyling practices and the risk of traction alopecia (TA). J Am Acad Dermatol. 2016;75(3):606–11.Google Scholar
  55. 55.
    Samrao A, Price VH, Zedek D, Mirmirani P. The, “Fringe Sign”: a useful clinical finding in traction alopecia of the marginal hair line. Dermatol Online J. 2011;17(11):1.Google Scholar
  56. 56.
    Lawson CN, Hollinger J, Sethi S, Rodney I, Sarkar R, Dlova N, et al. Updates in the understanding and treatments of skin & hair disorders in women of color. Int J Womens Dermatol. 2015;1(2):59–75.Google Scholar
  57. 57.
    Khumalo NP, Ngwanya RM. Traction alopecia: 2% topical minoxidil shows promise. Report of two cases. J Eur Acad Dermatol Venereol. 2007;21(3):433–4.Google Scholar
  58. 58.
    Barron-Hernandez YL, Tosti A. Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia. Expert Opin Investig Drugs. 2017;26(4):515–22.Google Scholar
  59. 59.
    Vergilis-Kalner IJ. Application of bimatoprost ophthalmic solution 0.03% for the treatment of eyebrow hypotrichosis: series of ten cases. Dermatol Online J. 2014;20:6.Google Scholar
  60. 60.
    Suwanchatchai W, Tanglertsampan C, Pengsalae N, Makornwattana M. Efficacy and safety of bimatoprost 0.03% versus minoxidil 3% in enhancement of eyebrows: a randomized, double-blind, split-face comparative study. J Dermatol. 2012;39(10):865–6.Google Scholar
  61. 61.
    Civas E, Aksoy B, Aksoy HM, Eski M, Yucel K. Hair transplantation for therapy-resistant alopecia areata of the eyebrows: is it the right choice? J Dermatol. 2010;37(9):823–6.Google Scholar
  62. 62.
    Toscani M, Fioramonti P, Ciotti M, Scuderi N. Single follicular unit hair transplantation to restore eyebrows. Dermatol Surg. 2011;37(8):1153–8.Google Scholar
  63. 63.
    Lee S, Tanglertsampan C, Tanchotikul M, Worapunpong N. Minoxidil 2% lotion for eyebrow enhancement: a randomized, double-blind, placebo-controlled, spilt-face comparative study. J Dermatol. 2014;41(2):149–52.Google Scholar
  64. 64.
    Sinclair R. Treatment of monilethrix with oral minoxidil. JAAD Case Rep. 2016;2(3):212–5.Google Scholar
  65. 65.
    Vikramkumar AG, Kuruvila S, Ganguly S. Monilethrix: a rare hereditary condition. Indian J Dermatol. 2013;58(3):243.Google Scholar
  66. 66.
    Rossi A, Iorio A, Scali E, Fortuna MC, Mari E, Palese E, et al. Monilethrix treated with minoxidil. Int J Immunopathol Pharmacol. 2011;24(1):239–42.Google Scholar
  67. 67.
    Oliveira EF, Araripe AL. Monilethrix: a typical case report with microscopic and dermatoscopic findings. An Bras Dermatol. 2015;90(1):126–7.Google Scholar
  68. 68.
    Singh G, Miteva M. Prognosis and management of congenital hair shaft disorders with fragility-part I. Pediatr Dermatol. 2016;33(5):473–80.Google Scholar
  69. 69.
    Santos Z, Avci P, Hamblin MR. Drug discovery for alopecia: gone today, hair tomorrow. Expert Opin Drug Discov. 2015;10(3):269–92.Google Scholar
  70. 70.
    Yeager CE, Olsen EA. Treatment of chemotherapy-induced alopecia. Dermatol Ther. 2011;24(4):432–42.Google Scholar
  71. 71.
    Lotfi-Jam K, Carey M, Jefford M, Schofield P, Charleson C, Aranda S. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. J Clin Oncol. 2008;26(34):5618–29.Google Scholar
  72. 72.
    Shin H, Jo SJ, Kim DH, Kwon O, Myung SK. Efficacy of interventions for prevention of chemotherapy-induced alopecia: a systematic review and meta-analysis. Int J Cancer. 2015;136(5):E442–54.Google Scholar
  73. 73.
    Duvic M, Lemak NA, Valero V, Hymes SR, Farmer KL, Hortobagyi GN, et al. A randomized trial of minoxidil in chemotherapy-induced alopecia. J Am Acad Dermatol. 1996;35(1):74–8.Google Scholar
  74. 74.
    Granai CO, Frederickson H, Gajewski W, Goodman A, Goldstein A, Baden H. The use of minoxidil to attempt to prevent alopecia during chemotherapy for gynecologic malignancies. Eur J Gynaecol Oncol. 1991;12(2):129–32.Google Scholar
  75. 75.
    Rodriguez R, Machiavelli M, Leone B, Romero A, Cuevas MA, Langhi M, et al. Minoxidil (Mx) as a prophylaxis of doxorubicin-induced alopecia. Ann Oncol. 1994;5(8):769–70.Google Scholar
  76. 76.
    Tallon B, Blanchard E, Goldberg LJ. Permanent chemotherapy-induced alopecia: case report and review of the literature. J Am Acad Dermatol. 2010;63(2):333–6.Google Scholar
  77. 77.
    Kluger N, Jacot W, Frouin E, Rigau V, Poujol S, Dereure O, et al. Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Ann Oncol. 2012;23(11):2879–84.Google Scholar
  78. 78.
    Tran D, Sinclair RD, Schwarer AP, Chow CW. Permanent alopecia following chemotherapy and bone marrow transplantation. Australas J Dermatol. 2000;41(2):106–8.Google Scholar
  79. 79.
    Prevezas C, Matard B, Pinquier L, Reygagne P. Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer. Br J Dermatol. 2009;160(4):883–5.Google Scholar
  80. 80.
    Yang X, Thai KE. Treatment of permanent chemotherapy-induced alopecia with low dose oral minoxidil. Australas J Dermatol. 2016;57(4):e130–2.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of DermatologyNorthwestern UniversityChicagoUSA

Personalised recommendations